ESMO World GI Cancer Congress, Barcelona, June 29 – July 2
- This topic has 1 reply, 2 voices, and was last updated 8 years, 2 months ago by
.
-
Posts
-
Thanks for that Marion. If I come across any literature from it I will post here if I can. Will keep an eye out for abstracts etc.
And hope the other conference you are at right now is going well. What would we all do without you!
Hugs,
Gavin
The Cholangiocarcinoma supports this highly acclaimed conference focused on malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumors. Cholangiocarcinoma, a common malignancy, will be highlighted as well.
Sessions relevant to our cancer include:
Nutritional support in gastrointestinal cancer,
Cancer cachexia and sarcopenia in GI cancer: mechanism and ways to interfere with it.
Does peri-operative nutritional support improve the outcome in GI cancer patients?
Cholangiocarcinoma and gall bladder cancer.
Does response evaluation still matters in the era of targeted agents? Does it predict for outcome?
How can we evaluate best the activity of immune therapies in GI cancer?
Beyond RECIST 1.1.: Role of irRECIST, PET/CT and paired biopsies to evaluate the activity of immune therapies in GI cancer.
How relevant is tumor regression grade evaluation in rectal cancer?
The ESMO and ASCO clinical benefit scales: do they impact on our practice?Cholangiocrcinoma Foundation material will be on display. Please encourage your physician to pick up our brochures and accompanying material.
Marion
- The forum ‘Announcements’ is closed to new topics and replies.